New combo therapy aims to wipe out rectal cancer before surgery
NCT ID NCT04928807
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether a short course of radiotherapy followed by the immunotherapy drug camrelizumab plus chemotherapy works better than standard long-term chemoradiation for locally advanced rectal cancer. About 230 patients will be randomly assigned to one of the two treatments before surgery. The main goal is to see if the new approach leads to a higher rate of complete tumor disappearance (pathological complete response) at the time of surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Camrelizumab (an immunotherapy drug) combined with capecitabine and oxaliplatin chemotherapy, plus short-course radiotherapy
What this could lead to
If successful, this could offer a more effective pre-surgery treatment for locally advanced rectal cancer, potentially leading to higher rates of complete tumor disappearance and better long-term outcomes.
What could go wrong
This is a Phase 3 trial, but results are not yet available. The combination may cause more side effects than standard treatment, and the benefit may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China